Glass Maker Schott Said to Weigh IPO of $4 Billion Pharma Arm
(Bloomberg) -- Schott AG is exploring options for its business making test tubes and glass packaging for the pharmaceuticals industry, including a possible initial public offering, according to people familiar with the matter.
The specialist German glazing company is speaking with potential advisers about a listing of its pharma unit next year, the people said, asking not to be identified discussing confidential information. An IPO could value the business at about $4 billion, the people said.
Schott would have to carve out the unit before any listing, one of the people said. It may also explore other options for its pharma arm, including a possible sale, according to the people. Deliberations are ongoing and no final decisions have been taken, they said.
“Our pharmaceutical business is and will remain a core part of our growth strategy,” a representative for Schott said in an email. “Of course, we are constantly reviewing strategy and financing options.”
Schott makes glazing products used in everything from building exteriors to lasers. Its pharma division makes glass tubes for testing, containers for long term drug storage and components for bioprocessing. The company is owned by the Carl Zeiss Foundation, which also controls the lens maker and optoelectronics specialist Carl Zeiss AG.
IPOs worldwide have plummeted in the first quarter after a record showing in 2021, as volatility stoked by the war in Ukraine and soaring inflation sets investors on edge and scuppers deals. To be sure, bankers are betting on a recovery in the months ahead, fueled in part by a full pipeline of large listing candidates readying to tap public investors, and the green shoots of a stock market rebound.
©2022 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
